Total amount: € 0,00
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,118
Gungunes A. 1, Ozbek M. 1, Ginis Z. 2, Sahin M. 3, Demirci T. 1, Cakir Ozkaya E. 1, Karbek B. 1, Sayki Arslan M. 1, Ozturk Unsal I. 1, Tutal Akkaya E. 1, Ucan B. 1, Gultuna Ozguclu S. 4, Cakal E. 1, Topaloglu O. 1, Delibasi T. 1
1 Department of Endocrinology and Metabolic Diseases, Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey;
2 Department of Biochemistry, Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey;
3 Department of Endocrinology and Metabolic Diseases, School of Medicine, Ankara University, Ankara, Turkey;
4 Department of Immunology, School of Medicine, Ankara University, Ankara, Turkey
AIM: Nesfatin-1 was recently discovered anorexigenic peptide in the brain which is derived from nucleobindin-2. Central and peripheral administration of nesfatin-1, inhibits food intake, dose-dependently. Hyperthyroid patients have increased appetite and food intake with a craving for carbohydrate-rich food, at the beginning of disease, but the physiological mechanisms underlying this behavior is not known exactly. In this study, we investigated whether nesfatin-1 is involved in the regulation of appetite and body weight in hyperthyroidism, or not.
METHODS: A total of 70 patients with subclinical (35) and overt hyperthyroidism (35) compared with 35 control patients. Serum nesfatin-1 level was measured from all samples by commercial ELISA kit.
RESULTS: Serum nesfatin-1 levels were similar between three groups (P=0.293). After adjusting for age and body mass index, nesfatin-1 levels in control group was not different from subclinical and overt hyperthyroid group, respectively (P=0.567 and P=0.519).
CONCLUSION: These data showed that serum nesfatin-1 levels do not significant change in overt and subclinical hyperthyroidism.